Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT04028050
- Locations
- 🇮🇹
Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy
🇮🇹Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy
🇮🇹Ospedali Riuniti Di Ancona; Oncology, Ancona, Marche, Italy
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT04023994
- Locations
- 🇺🇸
PRA Health Sciences, Raleigh, North Carolina, United States
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT04024462
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳The 900th Hospital of PLA joint service support force, Fuzhou, China
🇨🇳Sun Yet-sen University Cancer Center, Guangzhou City, China
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT04000594
- Locations
- 🇳🇱
Centre For Human Drug Research; Research, Leiden, Netherlands
🇬🇧Leonard Wolfson Experimental Neurology Centre, London, United Kingdom
🇬🇧Manchester University NHS Foundation Trust (MFT), Manchester, United Kingdom
A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT03988907
- Locations
- 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT03977584
- Locations
- 🇨🇴
Grupo Neurociencias de Antioquia, Medellin, Colombia
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT03972306
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸University of Texas at Houston; Neurology, Houston, Texas, United States
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4176
- Registration Number
- NCT03969212
- Locations
- 🇯🇵
Uehara Clinic, Sapporo, Japan
🇺🇸Helios Clinical Research, Inc (former Ventavia Research Group), Kissimmee, Florida, United States
🇺🇸Mercury Clinical Research, Houston, Texas, United States
Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT03959332
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT03943550
- Locations
- 🇲🇩
ARENSIA Phase 1 Unit- Spitalul Clinic Republican Location, Chisinau, Moldova, Republic of
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇬🇪The Research Institute of Clinical Medicine, Tbilisi, Georgia